Table 1.
Clinical informations, genotypic and phenotypic characteristics of MRSA responsible for human colonization and infections
| Isolate | Patient gender | Patient age (years) | Type of infection | SCCmec type | spa type | ST | CC | PVL | ACME | Resistance pattern to non beta-lactam antibiotics§ |
|---|---|---|---|---|---|---|---|---|---|---|
| Colonization |
|
|
|
|
|
|
|
|
|
|
| Sau93 |
M |
67 |
- |
IVc |
t899 |
398 |
398 |
- |
- |
ERY, CLI, SXT, TET |
| Sau95 |
F |
77 |
- |
IVa |
t899 |
398 |
398 |
- |
- |
ERY, CLI, TET |
| Sau98 |
F |
58 |
- |
IVa |
t899 |
398 |
398 |
- |
- |
TET |
| Sau91 |
M |
40 |
- |
V |
t108 |
398 |
398 |
- |
- |
LVX #, TET |
| Sau99 |
M |
20 |
- |
V |
t2922 |
398 |
398 |
- |
- |
ERY, CLI, SXT, TET |
| Sau96 |
F |
61 |
- |
IVc |
t008 |
8 |
8 |
- |
- |
LVX, TET |
| Sau97 |
M |
66 |
- |
IVc |
t008 |
8 |
8 |
- |
- |
GN, LVX |
| Sau92 |
M |
71 |
- |
IVc |
t008 |
8 |
8 |
- |
- |
LVX |
| Sau94 |
F |
17 |
- |
V |
t688 |
5 |
5 |
- |
- |
ERY, CLI*, TET |
| Infections |
|
|
|
|
|
|
|
|
|
|
| Sau150 |
M |
18 |
SSTI |
IVa |
t008 |
8 |
8 |
+ |
+ |
LVX, ERY |
| Sau116 |
F |
71 |
SSTI |
IVa |
t008 |
8 |
8 |
+ |
+ |
LVX, ERY |
| Sau161 |
F |
27 |
SSTI |
IVa |
t008 |
8 |
8 |
+ |
+ |
LVX, ERY |
| Sau85 |
F |
46 |
SSTI |
IVa |
t121 |
8 |
8 |
+ |
- |
LVX, ERY |
| Sau86 |
F |
35 |
SSTI |
IVc |
t005 |
22 |
22 |
+ |
- |
ERY, CLI* |
| Sau149 |
M |
0.8 |
SSTI |
IVc |
t044 |
80 |
80 |
+ |
- |
FUS, TET |
| Sau151 |
F |
2 |
SSTI |
V |
t127 |
1 |
1 |
+ |
- |
GN, FUS, TET |
| Sau119 |
M |
38 |
SSTI |
V |
t7445 |
772 |
1 |
+ |
- |
GN, ERY, CLI* SXT, |
| Sau118 |
F |
53 |
SSTI |
IVc |
t008 |
8 |
8 |
- |
- |
LVX #, |
| Sau73 |
F |
70 |
SSTI |
IVc |
t008 |
8 |
8 |
- |
- |
LVX #, ERY, CLI* |
| Sau159 |
F |
85 |
SSTI |
IVc |
t008 |
8 |
8 |
- |
- |
LVX |
| Sau163 |
F |
53 |
SSTI |
IVc |
t008 |
8 |
8 |
- |
- |
GN, LVX, RIF |
| Sau84 |
M |
67 |
SSTI |
IVc |
t008 |
8 |
8 |
- |
- |
LVX, TET |
| Sau121 |
F |
83 |
BSI |
IVc |
t008 |
8 |
8 |
- |
- |
LVX |
| Sau82 |
F |
84 |
SSTI |
IVa |
t127 |
1 |
1 |
- |
- |
LVX, ERY, CLI* |
| Sau83 |
F |
9 |
SSTI |
IVa |
t127 |
1 |
1 |
- |
- |
ERY, CLI*, TET |
| Sau162 |
F |
61 |
OE |
IVa |
t127 |
1 |
1 |
- |
- |
GN, ERY, CLI*, TET |
| Sau120 |
M |
77 |
SSTI |
IVh |
t515 |
22 |
22 |
- |
- |
LVX # |
| Sau117 |
M |
79 |
SSTI |
I |
t041 |
228 |
5 |
- |
- |
GN, LVX, ERY, CLI, RIF# |
| Sau74 | M | 68 | OE | IVc | t899 | 398 | 398 | - | - | CLI, SXT, TET |
SCCmec staphylococcal cassette chromosome mec, ST sequence type, CC clonal complex, PVL Panton-Valentine Leukocidin, ACME arginine catabolic mobile element.
§ GEN gentamicin, ERY erythromycin, CLI clindamycin, LVX levofloxacin, FUS fusidic acid, TET tetracycline, SXT co-trimoxazole, RIF rifampicin, * inducible clindamycin resistance; # intermediate resistance.
SSTI skin and soft tissue infection, BSI bloodstream infection, OE otitis externa.